Unicycive Therapeutics, Inc.
UNCY
$0.696
$0.05819.11%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 102.65% | -425.51% | -141.56% | 147.01% | -168.83% |
| Total Depreciation and Amortization | 0.75% | 8.94% | 208.85% | -139.79% | 246.34% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -159.24% | 1,243.69% | 92.89% | -231.14% | 471.89% |
| Change in Net Operating Assets | -207.11% | 141.21% | -3,924.07% | -94.29% | 68.87% |
| Cash from Operations | -35.97% | 29.23% | -46.42% | 2.12% | -45.44% |
| Capital Expenditure | 27.27% | 8.33% | -20.00% | -233.33% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 27.27% | 8.33% | -20.00% | -233.33% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 308.49% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | 100.00% | -- | -- |
| Other Financing Activities | 23.27% | -102.55% | -155.28% | 106.59% | -2,001.95% |
| Cash from Financing | 597.53% | 332.48% | 80.64% | -101.77% | 22,388.29% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.71% | 34.22% | -31.93% | -118.23% | 944.72% |